Trial Profile
A Phase IIa, Open-label, Multicenter Study of Single-agent MOR00208, an Fc-optimized Anti-CD19 Antibody, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Tafasitamab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors MorphoSys
- 01 Apr 2022 Status changed from active, no longer recruiting to completed.
- 01 Apr 2022 Results published in the Clinical Lymphoma, Myeloma & Leukemia
- 05 Oct 2021 This trial has been completed in Germany, according to European Clinical Trials Database.